Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 8/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | ABL2 | P42684 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1459959 | 0.84 | KDR (0.46) | EGFRERBB2KDRABL1ABL2 | |
| SCHEMBL1460932 | 0.83 | KDR (0.70) | EGFRKDR | |
| SCHEMBL4052329 | 0.71 | KDR (0.53) | EGFRERBB2KDR | |
| SCHEMBL5740575 | 0.70 | EGFR (0.74) | EGFRERBB2KDRFBP1 | |
| SCHEMBL4042632 | 0.68 | EGFR (1.00) | EGFRERBB2KDR | |
| SCHEMBL1227705 | 0.67 | KDR (0.59) | EGFRKDR | |
| SCHEMBL1228137 | 0.67 | KDR (0.60) | EGFRKDR | |
| SCHEMBL14451955 | 0.67 | KDR (0.53) | EGFRERBB2KDR | |
| SCHEMBL5739893 | 0.67 | KDR (0.71) | EGFRERBB2KDR | |
| SCHEMBL1460928 | 0.66 | KDR (1.00) | EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1183033-B1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-03-01 | — | — | EP | claimed |
| US-6982265-B1 | Pyrrolotriazine inhibitors of kinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-01-03 | — | — | US | claimed |
| EP-1669071-B1 | Pyrrolotriazine inhibitors of kinases | BRISTOL MYERS SQUIBB CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7244733-B2 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-7112675-B2 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060128709-A1 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-15 | — | — | US | disclosed |
| EP-1669071-A1 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1183033-B1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20060004007-A1 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-6982265-B1 | Pyrrolotriazine inhibitors of kinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128709-A1 | Pyrrolotriazine inhibitors of kinases | FGFR1, FGFR2, ERBB2 | EGFR 27/4885ERBB2 3/4885KDR 8/4885 |
| US-20060004007-A1 | Pyrrolotriazine inhibitors of kinases | FGFR1, FGFR2, ERBB2 | EGFR 27/4885ERBB2 3/4885KDR 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.